| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
|
Medicine details |
|
| Medicine name | brigatinib (Alunbrig®) |
| Formulation | 30 mg, 90 mg, 180 mg film-coated tablet |
| Reference number | 3200 |
| Indication | As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small-cell lung cancer (NSCLC) previously treated with crizotinib |
| Company | Takeda UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/12/2018 |
| NICE guidance | TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |